The Goldman Sachs Group Issues Pessimistic Forecast for uniQure (NASDAQ:QURE) Stock Price

Posted by ABMN Staff on Mar 5th, 2026

uniQure (NASDAQ:QURE – Get Free Report) had its price objective lowered by stock analysts at The Goldman Sachs Group from $37.00 to $9.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. The Goldman Sachs Group’s target price suggests a potential downside of 0.44% from the company’s current price.

A number of other equities analysts have also commented on the stock. Wells Fargo & Company reissued an “equal weight” rating and issued a $15.00 price target (down from $60.00) on shares of uniQure in a research report on Tuesday. Wolfe Research initiated coverage on shares of uniQure in a research report on Monday, February 23rd. They issued a “peer perform” rating for the company. Benchmark restated a “buy” rating on shares of uniQure in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Finally, Sanford C. Bernstein downgraded uniQure to a “market perform” rating in a report on Tuesday. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $34.33.

Get Our Latest Report on QURE

uniQure Stock Performance

Shares of QURE stock opened at $9.04 on Tuesday. uniQure has a fifty-two week low of $7.76 and a fifty-two week high of $71.50. The stock’s 50-day moving average is $22.54 and its two-hundred day moving average is $29.57. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 7.12. The firm has a market cap of $565.27 million, a P/E ratio of -2.62 and a beta of 0.73.

uniQure (NASDAQ:QURE – Get Free Report) last announced its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.37. The business had revenue of $5.57 million during the quarter, compared to analysts’ expectations of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. Analysts predict that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the sale, the director owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. The trade was a 44.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Matthew C. Kapusta sold 12,378 shares of uniQure stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total transaction of $295,339.08. Following the completion of the transaction, the chief executive officer owned 639,076 shares of the company’s stock, valued at $15,248,353.36. This represents a 1.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 50,598 shares of company stock worth $1,248,588 in the last three months. Corporate insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

Large investors have recently added to or reduced their stakes in the company. Private Trust Co. NA purchased a new stake in uniQure during the 3rd quarter valued at $28,000. Jones Financial Companies Lllp lifted its position in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in uniQure by 5.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after buying an additional 533 shares during the last quarter. Arizona State Retirement System boosted its holdings in uniQure by 6.0% in the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after purchasing an additional 627 shares during the last quarter. Finally, Ensign Peak Advisors Inc lifted its holdings in uniQure by 21.7% in the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after acquiring an additional 650 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

Positive Sentiment: Q4 results beat expectations (EPS and revenue) and trading activity spiked after the release, which can support short‑term buying interest based on improved fundamentals and investor attention. uniQure (NASDAQ:QURE) Sees Unusually-High Trading Volume Following Strong Earnings
Positive Sentiment: Technicals: analysts at Zacks note heavy recent selling has pushed QURE into oversold territory and consensus estimate revisions are moving higher — a technical + analyst alignment that could prompt a trend reversal or short‑covering bounce. uniQure (QURE) Loses 67.5% in 4 Weeks, Here’s Why a Trend Reversal May be Around the Corner
Neutral Sentiment: Corporate/governance risk: uniQure disclosed it may fall under the Dutch “large company” regime next year, which would change shareholder control dynamics and could affect governance-related investor sentiment (longer‑term structural risk, not an immediate catalyst). uniQure Faces 2026 Shift to Dutch Large Company Regime, Curbing Direct Shareholder Control Over Board Appointments
Negative Sentiment: Regulatory setback: the FDA has told uniQure to conduct another study of its Huntington’s gene therapy and senior FDA officials expressed doubt the current data demonstrate benefit. This materially weakens near‑term approval prospects and is the biggest immediate negative for the stock. FDA tells uniQure to conduct another study of Huntington’s gene therapy
Negative Sentiment: Analyst downgrades and big price‑target cuts (Goldman, Wells Fargo, RBC, Mizuho and others) have followed the FDA news and earnings; several firms cut targets dramatically, lowering institutional support and amplifying selling pressure. uniQure (NASDAQ:QURE) Receives Equal Weight Rating from Wells Fargo & Company / price target changes
Negative Sentiment: Legal/market risk: multiple law firms have filed or issued shareholder alerts about securities class actions tied to disclosures in late‑2025; active litigation and associated headlines increase legal risk and can deter investors. SHAREHOLDER ALERT: Berger Montague Reminds UniQure N.V. (QURE) Investors of Class Action Lawsuit Deadline

About uniQure

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.